Contraindication Lifted for Concurrent Use of Adempas and HIV Protease Inhibitors

The Ministry of Health, Labor and Welfare (MHLW) on September 13 ordered label revisions to lift contraindications for the concurrent use of Bayer Yakuhin’s pulmonary arterial hypertension (PAH) treatment Adempas (riociguat) and HIV protease inhibitors. The protease inhibitors subject to...read more